Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The UAB ILD Center offers clinical trial enrollment for patients with idiopathic pulmonary fibrosis and other forms of diffuse parenchymal lung disease as part of a multidisciplinary and integrated ...

Lung transplantation remains a vital option for advanced IPF, with increasing transplant numbers and evolving allocation strategies. Idiopathic pulmonary fibrosis (IPF) is characterized by a ...

Oftentimes, the cause of lung scarring isn’t clear, so healthcare providers call it idiopathic pulmonary fibrosis, meaning ...

The term “progressive pulmonary fibrosis” or “PPF” is generally used to describe progressive lung fibrosis in an individual with an interstitial lung disease (ILD) other than idiopathic ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Interstitial lung disease (ILD) is a broad term for a group of conditions that cause lung inflammation and/or fibrosis (scarring ... and how the disease affects your lung structure and function. Some ...

Structure Therapeutics Inc ... Thus, a patient who has idiopathic pulmonary fibrosis has scarring/damage to the lungs with no known root cause. In essence, it just comes about randomly.

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

The UAB ILD Center offers clinical trial enrollment for patients with idiopathic pulmonary fibrosis and other forms of diffuse parenchymal lung disease as part of a multidisciplinary and integrated ...